Esomeprazole magnesium

This page contains recent news articles, when available, and an overview of Esomeprazole magnesium but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Esomeprazole magnesium (when available)

Pharmacology and use:
Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H⁺/K⁺ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, Omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. For the treatment of gastroesophageal reflux disease

Mechanism Of Action:
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H⁺/K⁺-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Omeprazole blocks the final step in acid production, thus reducing gastric acidity.

News Articles on Omeprazole

Romancing the Enemy Pays Off for Drug Companies  -  Aug 5, 2008
Ranbaxy will also manufacture Nexium’s active ingredient esomeprazole magnesium for AstraZeneca from May 2009. Beginning May 2010, Ranbaxy will also NJBIZ,

POZEN to Present at the 2008 BMO Capital Markets Focus on ...  -  Jul 24, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for MarketWatch

POZEN Receives Initial FDA Response To PA32540 SPA  -  Aug 2, 2008
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single FOXBusiness

POZEN Announces July 29, 2008 Webcast of Second Quarter 2008 Results  -  Jul 15, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for WELT ONLINE,

POZEN Reports Second Quarter 2008 Results  -  Jul 29, 2008
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single Business Wire (press release),

A Journey to Continence: A Case Study of Overactive Bladder Syndrome  -  Jul 23, 2008
Her prescribed medications included amlodipine besylate (Norvasc(R)) 10 mg, esomeprazole magnesium (Nexium(R)) 40 mg, venlafaxine hydrochloride (Effexor RedOrbit,

Dr Reddy's follows Teva on Nexium  -  Jun 5, 2008
...and Ranbaxy have also entered into a manufacturing contract for supply raw material for making esomeprazole magnesium to AstraZeneca from 2009 onwards. Sify,

Now, Ranbaxy seeks peace with Takeda  -  Jun 21, 2008
During the 180-day period following the date, Ranbaxy will distribute the only generic Esomeprazole magnesium product in the US market. Business Standard,

POZEN To Present at the Jefferies 2 nd Annual Healthcare Conference  -  Jun 16, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

AstraZeneca Submits sNDA for Nexium IV  -  Jun 6, 2008
...for 30 minutes plus an IV infusion of Nexium 8 mg per hour for 72 hours, followed by oral Nexium (esomeprazole magnesium) 40 mg once daily for 27 days. FDA news (subscription),

Indian drugs maker Ranbaxy taken over by Japan's Daiichi Sankyo  -  Jun 11, 2008
The Indian group will manufacture supplies of the active ingredient in the drug, esomeprazole magnesium, from May 2009. Times Online,

POZEN Demonstrates Bioequivalence To Enteric Coated Aspirin For ...  -  Jun 11, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Medical News Today (press release),

ESOMEPRAZOLE SODIUM - Drug information  -  02 Jun 2008
...as an alternative to oral therapy in patients when therapy with Nexium (esomeprazole magnesium) Delayed-Release Capsules is not possible or appropriate. Lifescience-online,

POZEN To Present at the Seventh Annual Needham & Co., LLC ...  -  02 Jun 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Ad-Hoc-News (Pressemitteilung),

POZEN To Present at the Seventh Annual Needham & Co., LLC ...  -  02 Jun 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

Settling it out  -  May 13, 2008
Two of these agreements concern esomeprazole magnesium capsules (the active ingredient in Nexium), while the third pertains to omeprazole 40mg tablets, Express Pharma,

AstraZeneca Submits sNDA for NEXIUM(R) IV for Peptic Ulcer Bleed ...  -  May 30, 2008
...an alternative to oral therapy in patients when therapy with NEXIUM(R) (esomeprazole magnesium) Delayed-Release Capsules is not possible or appropriate. Earthtimes (press release),

Healthy partnerships  -  May 11, 2008
The deal with Astra Zeneca on Esomeprazole magnesium, the generic equivalent of Nexium, the second largest selling drug in the US with sales of $5.5 billion Business Standard,

Pozen Announces PN 200 Podium Presentation at Digestive Disease Week  -  May 19, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for PharmaLive.com (press release),

POZEN Announces PN 200 Podium Presentation At Digestive Disease Week  -  May 21, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Medical News Today (press release),

AstraZeneca, Ranbaxy Ink Manufacturing Agreements  -  May 29, 2008
Under the agreements, generic drugmaker Ranbaxy will formulate a portion of AstraZeneca's US supply of Nexium (esomeprazole magnesium) starting in May 2010. Pharmaceutical Online (press release),

POZEN To Present at the Citigroup Global Healthcare Conference  -  May 15, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for PR-Inside.com (Pressemitteilung),

McKesson Sued for Alleged Drug Price Manipulation  -  May 22, 2008
...heartburn drug Nexium (esomeprazole magnesium) and diazepam, sold by Roche under the brand name Valium, as examples of allegedly overpriced drugs. FDA news (subscription),

Streetinvesting.com: POZEN To Present at the Citigroup Global ...  -  May 15, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Trading Markets (press release),

POZEN IND and NDA for Treximet™ (Sumatriptan/Naproxen Sodium ...  -  May 14, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

NPS Appoints Dr. Bo Joelsson as Head of Clinical Research  -  May 13, 2008
...development of several major gastrointestinal products, including Tagamet® (cimetidine), Prilosec® (omeprazole), and Nexium® (esomeprazole magnesium). Business Wire (press release),

Ranbaxy Q1 beats forecast; sees more growth  -  23 Apr 2008
Ranbaxy can also formulate a portion of AstraZeneca's US supply of Nexium from May 2010, with the active ingredient in the drug, esomeprazole magnesium, CNN-IBN,

Ranbaxy's net profit at USD 39mn (Rs 1530 mn), + 19%  -  Apr 22, 2008
Two of these agreements concern Esomeprazole magnesium capsules (Nexium), the second largest selling drug in the United States with sales of USD 5.5 Bn Moneycontrol.com (press release),

Ranbaxy, AstraZeneca settle Nexium suit  -  Apr 15, 2008
...submission to the United States Food & Drug Administration of an Abbreviated New Drug Application for esomeprazole magnesium's generic version. NDTV.com,

Ranbaxy to sell ulcer drug Nexium in US  -  Apr 15, 2008
During the 180 period following that date, Ranbaxy will distribute the only generic esomeprazole magnesium product in the US market. Economic Times,

AstraZeneca Settles Ranbaxy Lawsuit  -  Apr 15, 2008
India's Ranbaxy Laboratories Ltd. had submitted an application to the US Food and Drug Administration to make a generic version of esomeprazole magnesium, The Associated Press

Ranbaxy in several agreement with Astrazeneca  -  Apr 15, 2008
Two of these agreements concern Esomeprazole magnesium capsules. The third agreement pertains to Omeprazole 40mg tablets, and the fourth agreement pertains India Infoline.com,

Ranbaxy in out-of-court pact with AstraZeneca for Nexium  -  Apr 15, 2008
...“We are pleased with the agreement which will provide certainty as to the launch of a generic formulation of esomeprazole magnesium in the US market,�? said Financial Express,

:.AstraZeneca to outsource Nexium APIs from Ranbaxy  -  Apr 16, 2008
During the 180-day period following that date, Ranbaxy will be the sole distributor of the generic version of the drug (esomeprazole magnesium) in US. Indiaoutsourcewatch.com,

Isabel Maxwell  -  Apr 8, 2008
Nexium esomeprazole magnesium and Nexium. Dyspepsia pain, or burning 12. What is esomeprazole at 4 weeks treatment? The 3 treatment days. Israel Insider,

AstraZeneca settles row with Ranbaxy  -  Apr 15, 2008
2008, said that it had received tentative approval from the US Food and Drug Administration (USFDA) for marketing esomeprazole magnesium delayed-release Business Standard,

AZ stifles threat to No. 1 drug  -  Apr 17, 2008
Ranbaxy, which had submitted an application with the US Food and Drug Administration to make a generic of esomeprazole magnesium, could have begun selling The News Journal,

Ranbaxy settles patent issue with AstraZeneca  -  Apr 15, 2008
During the 180-day period following the date, Ranbaxy Pharma will be the only company to distribute Esomeprazole magnesium product in the US market. Sify,

AstraZeneca Agrees To Settle Nexium Patent Infringement Suit ...  -  Apr 15, 2008
AstraZeneca further announced that it signed agreement with Ranbaxy, which allows the latter to manufacture and distribute esomeprazole magnesium. RTT News,

Ranbaxy CEO says Nexium deal extremely positive  -  Apr 15, 2008
...a portion of AstraZeneca's US supply of Nexium from May 2010, with the active ingredient in the drug, esomeprazole magnesium, being made from May 2009. Reuters India,

AstraZeneca CEO says wants more outsourcing deals  -  Apr 15, 2008
Ranbaxy will formulate a portion of AstraZeneca's US supply of Nexium from May 2010, with the active ingredient in the drug, esomeprazole magnesium, Reuters

Corporate round-up: Mirchandani to buy out brother's stake in Onida  -  Apr 19, 2008
...‘a significant portion’ of Nexium for AstraZeneca from May 2010 and its active pharmaceutical ingredient (API), esomeprazole magnesium, from May 2009. Economic Times,

Nexium deal shot in arm for Ranbaxy  -  Apr 15, 2008
...to supply AstraZeneca, the active pharmaceutical ingredient or the drug itself, that is branded and sold as Nexium called esomeprazole magnesium. Daily News & Analysis,

AstraZeneca settles with Ranbaxy to stave off generic Nexium launch  -  Apr 15, 2008
Ranbaxy will also manufacture the active ingredient in the drug, esomeprazole magnesium, starting in May 2009, and Ranbaxy becomes the US distributor for Medical Marketing and Media,

Ranbaxy sees $1.25 bln to $1.50 bln in revenue from AstraZeneca deal  -  Apr 15, 2008
Ranbaxy will also manufacture finished dosages of Nexium from May 2010 for AstraZeneca, and Esomeprazole Magnesium, the active pharmaceutical ingredient in MarketWatch

AstraZeneca shares soar as patent case settled  -  Apr 15, 2008
The Indian group will manufacture supplies of the active ingredient in the drug, esomeprazole magnesium, from May 2009. The FTSE 100 group said that the Times Online,

AstraZeneca agrees deal with Indian generic firm over key drug  -  Apr 15, 2008
That will include the manufacture of esomeprazole magnesium, the active pharmaceutical ingredient in Nexium, from May 2009. Nexium, which treats stomach AFP

AstraZeneca settles Nexium dispute with Ranbaxy Laboratories  -  Apr 15, 2008
The Indian group will manufacture supplies of the active ingredient in the drug - esomeprazole magnesium - from May 2009. AstraZeneca said that the deal Times Online,

Ranbaxy settles Nexium suit  -  Apr 16, 2008
...to the United States Food and Drug Administration (USFDA) of an abbreviated new drug application for the generic version of esomeprazole magnesium. Calcutta Telegraph,

AstraZeneca says Ranbaxy can sell generic Nexium under licence ...  -  Apr 15, 2008
Nexium from May 2010, including provisions for the manufacture of esomeprazole magnesium, the active pharmaceutical ingredient in Nexium, from May 2009. CNNMoney.com

Ranbaxy settles lawsuit with AstraZeneca  -  Apr 15, 2008
Esomeprazole magnesium capsules, sold as Nexium, had sales of $3.4 billion (Rs13,600 crore) in the US and $5.2 billion globally in 2007—second only to Livemint,

BUYINS.NET: FTWR, ICXT, POZN, ACTC, EDNE, LNVGY Have Also Been On ...  -  Apr 14, 2008
...of the proton pump inhibitor (PPI) esomeprazole magnesium, with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet. Trading Markets (press release),

FDA Approves Nexium for Use in Children Ages 1-11 Years  -  11 Mar 2008
...(March 10, 2008)-- The US Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the Compliance Home,

FDA Okays Esomeprazole (Nexium) for Pediatric GERD  -  Feb 28, 2008
28 -- The FDA today approved esomeprazole magnesium (Nexium) for short-term treatment of gastroesophageal reflux disease (GERD) in children ages one year to MedPage Today,

FDA Clears Astra’s GERD Drug Nexium for Children Ages 1-11 Years  -  Feb 29, 2008
By Anna Boyd The US Food and Drug Administration on Thursday approved esomeprazole magnesium, also known as Nexium for short treatment of gastroesophageal eFluxMedia

AstraZeneca Beats Back Legal Challenge by Pharmacies  -  Feb 27, 2008
...switched market demand from the prescription version of Prilosec (omeprazole magnesium) to an OTC version and Nexium (esomeprazole magnesium). FDA news (subscription),

FDA OKs Nexium for use in children  -  Feb 28, 2008
28 (UPI) -- The US Food and Drug Administration has approved Nexium (esomeprazole magnesium) for short-term use in children less than 12 years of age. United Press International

FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in ...  -  Feb 28, 2008
The new 10 mg dose formulation contains esomeprazole magnesium, the same active ingredient used in NEXIUM Delayed-Release Capsules. Earthtimes,

AstraZeneca, Nomura Phase4 Create GI Venture  -  Feb 21, 2008
The spinout is a result of AstraZeneca’s decision to concentrate on Nexium (esomeprazole magnesium) and internal GI research focused on gastroesophageal FDA news (subscription),

FDA Approves Esomeprazole for Use in Children Ages 1-11 Years  -  Feb 28, 2008
ROCKVILLE, Md -- February 28, 2008 -- The US Food and Drug Administration approved esomeprazole magnesium (Nexium) for short-term use in children ages 1 to DG News

FDA Doubles the Good News for AstraZeneca  -  Mar 6, 2008
The safety and tolerability of Nexium (esomeprazole magnesium) in this age group was established in a multicenter, randomized, double-blind, open-label, FDA news (subscription),

GERD Drug Approved for Younger Children  -  Feb 28, 2008
Two forms of Nexium (esomeprazole magnesium) were approved for younger children -- a delayed-release capsule and a liquid form. Doses approved for this age Forbes,

FDA approves Nexium for children aged 1-11  -  Feb 28, 2008
Canada (containing esomeprazole magnesium) in strengths of 20 mg and 40 mg for adults; and as esomeprazole sodium for intravenous injection/infusion. Pravda,

FDA Accepts Astra Zeneca's Nexium For Children Aged 1 to 11  -  Feb 29, 2008
Nexium (esomeprazole magnesium) is a proton pump inhibitor that reduces the amount of stomach acid produced and helps heal damage to the esophagus due to AHN

Ranbaxy Gets OK for Generic Nexium  -  Feb 14, 2008
Ranbaxy said it was the first to submit an ANDA for generic Nexium (esomeprazole magnesium) 20- and 40-mg delayed-release capsules, potentially providing FDA news (subscription),

Nexium Now Approved for Children Ages 1-11  -  Feb 28, 2008
Nexium (esomeprazole magnesium) is used to treat gastroesophageal reflux disease (GERD). The two approved forms of Nexium for children ages 1-11 are the Associated Content,

SRS Labs Appoints Allen Gharapetian As VP, Marketing - Quick Facts ...  -  Feb 28, 2008
2/28/2008 9:31:43 AM AstraZeneca plc (AZN) announced that the US Food and Drug Administration has approved the use of Nexium (esomeprazole magnesium) in RTT News,

Brand Names/Synonyms:
Esomeprazole magnesium is also known by the following brand names and/or synonymsAntra; Antra Mups; Audazol; Aulcer; Belmazol; CCRIS 7099; Ceprandal; Danlox; Demeprazol; Desec; Dizprazol; Dudencer; Elgam; Emeproton; Epirazole; Erbolin; Esomeprazole; Esomeprazole Magnesium; Exter; Gasec; Gastrimut; Gastroloc; Gibancer; H 168/68; HSDB 3575; Indurgan; Inhibitron; Inhipump; Lensor; Logastric; Lomac; Losec; Mepral; Miol; Miracid; Mopral; Morecon; Nexium; Nexium Iv; Nilsec; Nopramin; OMEP; OMEPRAZOLE; OMP; OMZ; Ocid; Olexin; Omapren; Omebeta 20; Omed; Omegast; Omepral; Omeprazol [Inn-Spanish]; Omeprazole; Omeprazole [Usan:Ban:Inn:Jan]; Omeprazolum [Inn-Latin]; Omeprazon; Omeprol; Omesek; Omezol; Omezolan; Omid; Omisec; Omizac; Ompanyt; Ortanol; Osiren; Ozoken; Paprazol; Parizac; Pepticum; Pepticus; Peptilcer; Prazentol; Prazidec; Prazolit; Prilosec; Prilosec Otc; Procelac; Proclor; Prysma; Ramezol; Regulacid; Result; Sanamidol; Secrepina; Tedec Ulceral; Ulceral; Ulcesep; Ulcometion; Ulcozol; Ulcsep; Ulsen; Ultop; Ulzol; Victrix; Zefxon; Zegerid; Zepral; Zimor; Zoltum

Drug Category:
Esomeprazole magnesium is categorized under the following by the FDA: Anti-ulcer Agents; Proton-pump Inhibitors; ATC:A02BC01; ATC:A02BC05

Dosage Forms:
Oral tablets

Absorption:
Absorption is rapid, Absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg

Interactions:
-->Interactions for Omeprazole:

Other

Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole.

Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole.

Combination Therapy with Clarithromycin

Co-administration of omeprazole and clarithromycin may result in increases in plasma levels of ompeprazole, clarithromycin, and 14-hydroxy-clarithromycin.

Concomitant administration of clarithromycin with cisapride, pimozide, or terfenadine is contraindicated.

There have been reports of an intereaction between erythromycin and astemizole resulting in QT prolongation and torsades de points. Concomitant administration of erythromycin and astemizole is contraindicated. Because clarithromycin is also metabolized by cytochrome P450, concomitant administration of clarithromycin with astemizole is not recommended.

Chemical IUPAC Name:
5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.